title: Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary report.
abstract: OBJECTIVE
  The various prostate biopsy methods are usually compared in terms of the diagnosis rate of prostate cancer. However, the prevalence of cancer in patients with a negative prostatic biopsy is not usually known. We determined the sensitivity and detection rate of 12-core transperineal biopsies in patients not previously investigated for prostate cancer.
  
  
  METHODS
  We performed prostate biopsy in 63 patients (median age 67 years) before radical cystoprostatectomy for high-grade bladder cancer. We then assessed the relationships between biopsy result, prostate cancer in the surgical specimen, and other variables.
  
  
  RESULTS
  17.2% of patients had a positive biopsy and 54% had prostate cancer on definitive histology. Biopsy sensitivity was 32.3% overall, 75% for clinically significant cancers, and 11% for non-significant cancers. Median PSA was 1.2ng/ml, PSA levels did not correlate with the presence of prostate cancer, the presence of clinically significant cancer, bioptic diagnosis, or prostate volume. Age correlated with risk of cancer.
  
  
  CONCLUSIONS
  According to autopsy series, the prevalence of prostate cancer is greater than 50% in males older than 60, yet low PSA levels do not reliably indicate disease absence. The sensitivity of double sextant biopsy is unsatisfactory overall (32%), but acceptable (75%) for diagnosing clinically significant cancer.
authors.affiliation: Division of Urology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. bernardo.rocco@ieo.it
authors.forename: Bernardo
authors.initials: B
authors.lastname: Rocco
authors.forename: Ottavio
authors.initials: O
authors.lastname: de Cobelli
authors.forename: Maria Elena
authors.initials: ME
authors.lastname: Leon
authors.forename: Mario
authors.initials: M
authors.lastname: Ferruti
authors.forename: Mauro G
authors.initials: MG
authors.lastname: Mastropasqua
authors.forename: Deliu Victor
authors.initials: DV
authors.lastname: Matei
authors.forename: Giacomo
authors.initials: G
authors.lastname: Gazzano
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Verweij
authors.forename: Epifanio
authors.initials: E
authors.lastname: Scardino
authors.forename: Gennaro
authors.initials: G
authors.lastname: Musi
authors.forename: Bob
authors.initials: B
authors.lastname: Djavan
authors.forename: Francesco
authors.initials: F
authors.lastname: Rocco
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy / Q000379:methods; D015653:Cystectomy; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010502:Perineum; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
chemical_list: D017430:Prostate-Specific Antigen